论文部分内容阅读
目的探讨CAF联合化疗方案的新辅助化疗对乳腺癌组织BCSG1蛋白表达的影响。方法采用免疫组化SP法分别检测34例行CAF联合方案新辅助化疗患者(新辅助化疗组)和同期110例未行新辅助化疗患者(对照组)手术切除的乳腺癌组织BCSG1蛋白表达。同时对新辅助化疗组疗效进行病理形态学评价,并分析BCSG1蛋白表达与病理形态学变化的关系。结果新辅助化疗组化疗总有效率为79．4％。新辅助化疗组BCSG1蛋白高表达率明显低于对照组(29．4％比64．5％,P<0．01),化疗后部分缓解(Ⅱ级)病例BCSG1蛋白高表达水平明显低于无效(Ⅲ级)病病(P=0．002)。结论采用CAF方案新辅助化疗近期疗效明显,可抑制乳腺癌BCSG1蛋白的表达。
Objective To investigate the effect of neoadjuvant chemotherapy combined with chemotherapy on the expression of BCSG1 protein in breast cancer. Methods The expression of BCSG1 protein was detected by immunohistochemical SP method in 34 patients with neoadjuvant chemotherapy (neoadjuvant chemotherapy) and 110 patients without neoadjuvant chemotherapy (control group). At the same time, the therapeutic effect of neoadjuvant chemotherapy was evaluated by pathomorphology, and the relationship between BCSG1 protein expression and pathological changes was analyzed. Results The total effective rate of neoadjuvant chemotherapy was 79.4%. The high expression rate of BCSG1 protein in neoadjuvant chemotherapy group was significantly lower than that in control group (29.4% vs 64.5%, P <0.01). The high expression of BCSG1 protein in partial remission (grade Ⅱ) patients after chemotherapy was significantly lower than that in control group (Grade III) disease (P = 0.002). Conclusions The neoadjuvant chemotherapy with CAF regimen has obvious curative effect recently and can inhibit the expression of BCSG1 protein in breast cancer.